Elcelyx Therapeutics is developing safe products based on novel Gut Sensory Modulation (GSM) technology to address unmet needs in both the pharmaceutical and consumer markets.  The company has demonstrated clinical proof-of-concept for two proprietary products, each representing large market opportunities.  NewMet™ is being developed for the treatment of Type 2 diabetes and Lovidia™ for weight management.